Palisade Bio PALI
NASDAQ PALI
$1.13 -0.06 (-5.04%)
At close: Nov 10, 2026 · 4:00 PM EST

Palisade Bio (PALI) Current Deferred Revenue (2011)

Updated

Palisade Bio (PALI) recorded Current Deferred Revenue of $52,833 in Q3 2011.

Analysis

Palisade Bio (PALI) Current Deferred Revenue (2011) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Palisade Bio 249.43 Mn -147.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2011 52,833.00
API Access

Palisade Bio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=PALI&period=max&api_key=YOUR_API_KEY